All In Biotech

Drug Trial Radar · NCT04636814

A 52-week, Placebo- and Active- Controlled (Roflumilast, Daliresp® 500µg) Study to Evaluate the Efficacy and Safety of Two Doses of CHF6001 DPI (Tanimilast) as add-on to Maintenance Triple Therapy in Subjects With COPD and Chronic Bronchitis. (PILLAR)

A 52-week, Randomized, Double-blind, Double-dummy, Placebo- and Active- Controlled (Roflumilast, Daliresp® 500µg), Parallel Group, Study to Evaluate the Efficacy and Safety of Two Doses of CHF6001 DPI add-on to Maintenance Triple Therapy in Subjects With Chronic Obstructive Pulmonary Disease (COPD) and Chronic Bronchitis.

Last checked: Nov 19, 2026Latest source record: Feb 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedPivotal-lookingPhase 3. Randomized with 3,973 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

3,973

Actual

Start

Jul 12, 2021

Primary completion

Dec 23, 2025

Study completion Dec 23, 2025

Sponsor

Lead sponsor
Chiesi Farmaceutici S.p.A.Industry
Sponsor type
Industry
First posted
Nov 19, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 40 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the efficacy and the safety of two doses of CHF6001 (Tanimilast) as add-on to maintenance triple therapy in the target patient population.

Conditions

  • Chronic Obstructive Pulmonary Disease

Interventions

  • CHF6001 1600µgDrug

    CHF6001 400µg, 2 inhalations bid (total daily dose of 1600µg) and Roflumilast matching placebo, 1 tablet once daily

  • CHF6001 3200µgDrug

    CHF6001 800µg, 2 inhalations bid (total daily dose of 3200µg) and Roflumilast matching placebo, 1 tablet once daily

  • PlaceboDrug

    CHF6001 matching placebo, 2 inhalations bid and Roflumilast matching placebo, 1 tablet once daily

  • RoflumilastDrug

    \- 1 tablet of Roflumilast (Daliresp®), 250µg, once daily during the first 4 weeks of treatment then 1 tablet of Roflumilast (Daliresp®), 500µg, once daily for the remaining treatment period and CHF6001 matching placebo, 2 inhalations bid

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The number of moderate and severe exacerbations occurring during the planned 52-week treatment period.Time frame: Up to 52 weeks

Locations

460 sites in 28 countries. Site status is shown where the registry gives one.

  • Chiesi Clinical Trial - Site 840635

    Andalusia, Alabama

  • Chiesi Clinical Trial - Site 840614

    Foley, Alabama

  • Chiesi Clinical Trial - Site 840670

    Guntersville, Alabama

  • Chiesi Clinical Trial - Site 840720

    Mobile, Alabama

  • Chiesi Clinical Trial - Site 840643

    Saraland, Alabama

  • Chiesi Clinical Trial - Site 840638

    Phoenix, Arizona

  • Chiesi Clinical Trial - Site 840684

    Conway, Arkansas

  • Chiesi Clinical Trial - Site 840675

    Laguna Hills, California

  • Chiesi Clinical Trial - Site 840666

    Los Angeles, California

  • Chiesi Clinical Trial - Site 840511

    Newport Beach, California

  • Chiesi Clinical Trial - Site 840680

    Northridge, California

  • Chiesi Clinical Trial - Site 840605

    Northridge, California

  • Chiesi Clinical Trial - Site 840700

    Pomona, California

  • Chiesi Clinical Trial - Site 840531

    Westminster, California

  • Chiesi Clinical Trial - Site 840636

    Centennial, Colorado

  • Chiesi Clinical Trial - Site 840688

    Lakewood, Colorado

  • Chiesi Clinical Trial - Site 840735

    Brooksville, Florida

  • Chiesi Clinical Trial - Site 840513

    Chiefland, Florida

  • Chiesi Clinical Trial - Site 840652

    Clearwater, Florida

  • Chiesi Clinical Trial - Site 840569

    Clearwater, Florida

  • Chiesi Clinical Trial - Site 840545

    Coral Gables, Florida

  • Chiesi Clinical Trial - Site 840603

    Cutler Bay, Florida

  • Chiesi Clinical Trial - Site 840587

    Cutler Bay, Florida

  • Chiesi Clinical Trial - Site 840568

    Cutler Bay, Florida

  • Chiesi Clinical Trial - Site840539

    Daytona Beach, Florida

  • Chiesi Clinical Trial - Site 840554

    DeBary, Florida

  • Chiesi Clinical Trial - Site 840625

    Doral, Florida

  • Chiesi Clinical Trial - Site 840572

    Doral, Florida

  • Chiesi Clinical Trial - Site 840685

    Hialeah, Florida

  • Chiesi Clinical Trial - Site 840504

    Hialeah, Florida

  • Chiesi Clinical Trial - Site 840639

    Hialeah, Florida

  • Chiesi Clinical Trial - Site 840582

    Hialeah, Florida

  • Chiesi Clinical Trial - Site 840617

    Hialeah, Florida

  • Chiesi Clinical Trial - Site 840514

    Hialeah, Florida

  • Chiesi Clinical Trial - Site 840637

    Hialeah Gardens, Florida

  • Chiesi Clinical Trial - Site 840509

    Hollywood, Florida

  • Chiesi Clinical Trial - Site 840730

    Hollywood, Florida

  • Chiesi Clinical Trial - Site 840565

    Homestead, Florida

  • Chiesi Clinical Trial - Site 840674

    Loxahatchee Groves, Florida

  • Chiesi Clinical Trial - Site 840732

    Melbourne, Florida

Showing 40 of 460 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.